Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions: Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system; Combination Product
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetic Retinopathy
Interventions: Retinal imaging, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Diabetic Macular Edema
Interventions: Iluvien 0.19 MG Drug Implant, Aflibercept; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more

Conditions: Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Center-involved Diabetic Macular Edema (CI-DME)
Interventions: Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day; Dietary Supplement · Other
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Olympia, Washington • Tacoma, Washington

Conditions: Active Noninfectious Uveitis Affecting the Posterior Segment
Interventions: REGN7041; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more

Conditions: Eye Disease, Eye Care
Interventions: tailored newsletter, targeted newsletter; Behavioral
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 65 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: Brolucizumab, Aflibercept; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 74
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: STAKEL; Drug
Lead sponsor: Steba Biotech S.A.; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas

Conditions: Retinopathy, Diabetic
Interventions: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]; Drug
Lead sponsor: Ophthalmic Consultants of the Capital Region; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Troy, New York

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Pemafibrate, Placebo; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 69
States / cities: Phoenix, Arizona • Campbell, California • Glendale, California + 52 more

Conditions: Diabetic Retinopathy
Interventions: RETeval; Device
Lead sponsor: Inoveon Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Decatur, Georgia • Oklahoma City, Oklahoma

Conditions: Glaucoma, Ocular Hypertension
Interventions: Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetic Nephropathy, Diabetic Retinopathy
Interventions: CIIIT; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1995
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Telangiectasia
Interventions: Ranibizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy
Interventions: Color fundus photography, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Timeline: 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Retinopathy
Interventions: RO7663498; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Glendale, California • Oak Forest, Illinois • Columbus, Ohio + 1 more

Conditions: Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions: Intravitreal Aflibercept Injection; Drug
Lead sponsor: Ophthalmic Consultants of Boston; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Retinopathy
Interventions: Peribulbar Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy
Interventions: BI 765128, Sham comparator; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more

Conditions: Diabetes Mellitus, Macular Edema
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions: Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%; Drug · Procedure
Lead sponsor: Harrow Inc; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Diabetic Retinopathy
Interventions: I-SITE; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more

Search by objective public record fields.

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Assessment of EyeArt Performance With Retinal Cameras

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Tracking Optical Coherence Tomography

Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

Tailored Messages to Increase Eye Examination Behavior

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

PROMINENT-Eye Ancillary Study (Protocol AD)

RETeval Study for Diabetic Retinopathy

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

Laser and Medical Treatment of Diabetic Macular Edema

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity